Cargando…

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial

There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yhim, Ho-Young, Yoon, Dok Hyun, Kim, Seok Jin, Yang, Deok-Hwan, Eom, Hyeon-Seok, Kim, Kyoung Ha, Park, Yong, Kim, Jin Seok, Kim, Hyo Jung, Suh, Cheolwon, Kim, Won Seog, Kwak, Jae-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463683/ https://www.ncbi.nlm.nih.gov/pubmed/32781541 http://dx.doi.org/10.3390/cancers12082192

Ejemplares similares

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study
por: Kim, Seok Jin, et al.
Publicado: (2016)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
por: Yhim, Ho-Young, et al.
Publicado: (2010)

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
por: Jeong, Seong Hyun, et al.
Publicado: (2022)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)
por: Yoon, Dok Hyun, et al.
Publicado: (2016)

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
por: Kim, Yu Ri, et al.
Publicado: (2023)

Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement
por: Kim, Seon Young, et al.
Publicado: (2013)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
por: Yi, Jun Ho, et al.
Publicado: (2021)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
por: Yi, Jun Ho, et al.
Publicado: (2023)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study
por: Lee, Seul, et al.
Publicado: (2015)

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2017)

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
por: Yoon, Sang Eun, et al.
Publicado: (2020)

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
por: Cho, Hyungwoo, et al.
Publicado: (2023)

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
por: Hong, Junshik, et al.
Publicado: (2015)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

S229: PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA: A PHASE III RANDOMIZED, CONTROLLED STUDY
por: Yahng, Seung-Ah, et al.
Publicado: (2023)

Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology
por: Ahn, Yongchel, et al.
Publicado: (2017)

Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party
por: Suh, Cheolwon, et al.
Publicado: (2013)

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Seok Jin, et al.
Publicado: (2011)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry
por: Yi, Hyeon Gyu, et al.
Publicado: (2013)

Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
por: Seo, Jeongkuk, et al.
Publicado: (2017)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
por: Oh, Sung Yong, et al.
Publicado: (2019)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
por: Kim, Seok Jin, et al.
Publicado: (2023)

Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update
por: Hong, Jung Yong, et al.
Publicado: (2016)

The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160)
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
por: Yi, Jun Ho, et al.
Publicado: (2021)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
por: Eom, Ki-Seong, et al.
Publicado: (2014)

Primary Histiocytic Sarcoma of the Central Nervous System
por: So, Hoonsub, et al.
Publicado: (2015)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Case series of precursor B-cell lymphoblastic lymphoma
por: Kim, Jin Yong, et al.
Publicado: (2014)

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
por: Huang, Huiqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5mnqnb98e52aeggqqejenp0tcd